MANILA, Philippines — MSD in the Philippines, a trade name of Merck & Co. Inc., has announced the appointment of Andreas Riedel as its new president and managing director. He succeeds Dr. Beaver Tamesis who has announced his retirement from the pharmaceutical company.
The leadership transition reaffirms the company’s commitment of inventing for life, for Filipino patients. Riedel brings with him more than 20 years of experience in regional and local roles in the emerging markets, including Argentina, Chile, and the Philippines. As chair of Business Sustainability and board of directors member for the Pharmaceutical and Healthcare Association of the Philippines, he was pivotal in shaping the Philippine healthcare environment through programs created for long-term sustainability.
Prior to joining MSD, he was the country manager of Pfizer Philippines, where he developed an enterprise-wide strategic plan that improved health outcomes of populations and greatly impacted patients’ lives. With special focus on Market Access, he laid the foundation for the largest COVID-19 vaccine agreement with the local government.
His strong background in population health will boost up the company’s capability in closing the gap between pharmaceutical innovation and access to groundbreaking medicines, two areas that MSD in the Philippines actively advances.
Riedel steps into the role as the Philippines is currently experiencing a manifold health concerns in the areas of cancer, cardiovascular and metabolic diseases, vaccine preventable diseases, antimicrobial resistance, and COVID, among others